Search NEOG
Neogen Corporation
NasdaqGS · CIK 711377
Last close12.15
Daily change-0.09 (-0.74%)
10 Years gain-42.03%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
NEOG · STANDARD
SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Fiscal year end 0531
Fundamental
19.6Momentum
3.8Acceleration
18.4Confidence
92.0Annual Revenue17
Quarterly Revenue73
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.6 / 25
Quality9.1 / 25
Capital Efficiency0.0 / 20
Balance Sheet4.2 / 15
Shareholder Economics5.7 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Negative FCF · HIGHLatest free cash flow is negative.
Gross margin compression · MEDIUMGross margin compressed by 3.0305 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 9.2344 percentage points.
Key Metrics
Revenue Growth TTM-7.07%OK
Revenue CAGR 3Y1.91%OK
Gross Margin47.45%OK
Operating Margin-2.24%OK
FCF Margin-0.89%OK
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-0.5%OK
Incremental Operating Margin 3Y-19.04%OK
Net Debt / CFO8.74xOK
Diluted Share Growth 1Y0.39%OK
SBC / Revenue1.69%OK
SBC / FCF-188.4%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 FY May 31, 2026 | $870.40M | $408.50M | -$21.60M | $83.20M | $31.90M | 46.93% | -2.48% | 3.67% | -0.62% | 217.5M |
| 2026 FY May 31, 2025 | $894.70M | $421.40M | -$1.06B | $58.20M | -$46.40M | 47.1% | -118.59% | -5.19% | -25.02% | 216.9M |
| 2026 FY May 31, 2024 | $924.20M | $463.90M | $58.60M | $35.30M | -$76.10M | 50.19% | 6.34% | -8.23% | 1.21% | 216.5M |
| 2025 FY May 31, 2023 | $822.45M | $405.96M | $37.52M | $41.03M | -$24.73M | 49.36% | 4.56% | -3.01% | 1.38% | 188.88M |
| 2024 FY May 31, 2022 | $527.16M | $243.01M | $58.62M | $68.04M | $43.61M | 46.1% | 11.12% | 8.27% | 9.74% | 108.02M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $866.08M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-149599, 0001193125-25-235720 |
| Revenue Growth TTM | -7.07% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-149599, 0001193125-25-235720 |
| Revenue CAGR 3Y | 1.91% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-326092 |
| Revenue CAGR 5Y | 13.19% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-326092 |
| Gross Profit CAGR 3Y | 0.21% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-326092 |
| Operating Income Growth | -129.7% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001193125-26-149599, 0001193125-25-235720 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-149599, 0001193125-26-007682 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 47.45% | Gross Profit / Revenue | OK | 0001193125-26-149599, 0001193125-25-235720 |
| Operating Margin | -2.24% | Operating Income / Revenue | OK | 0001193125-26-149599, 0001193125-25-235720 |
| FCF Margin | -0.89% | (CFO - CapEx) / Revenue | OK | 0001193125-26-149599, 0001193125-26-007682 |
| ROIC | -0.5% | NOPAT / Average Invested Capital | OK | 0001193125-26-149599, 0001193125-25-235720 |
| Net Debt / CFO | 8.74x | Net Debt / CFO | OK | 0001193125-26-149599, 0001193125-26-007682 |
| Current Ratio | 3.92x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.2x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-149599 |